CHEST Physician
-
COURSE trial shows importance of biomarker testing in COPD
While overall the trial was negative, Meilan King Han, MD, MS, and Sanjay Ramakrishnan, MBBS, PhD, said it demonstrated the promise of tezepelumab for patients with baseline blood eosinophil counts ≥ 150 cells/µL.
-
Procalcitonin levels may guide antibiotic duration in patients with suspected sepsis
Paul Dark, MD, PhD, said a 10% reduction in duration of antibiotic use shown in a recent study may seem small, but in the context of antibiotic stewardship, a 10% reduction is important.
-
Admilparant phase 2 results raise hopes for combination treatment in pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are associated with irreversible loss of lung function with a poor prognosis. Now, a recent phase 2 trial of admilparant, a […]
-
Dupilumab reverses airway inflammation, mucus hypersecretion in type 2 asthma
Lead author Mario Castro, MD, MPH, FCCP, said the VESTIGE trial is one of the first to show that we can reverse the disease process in asthma and substantially improve lung function.
-
Hope on the horizon for bronchiectasis
The combination of personalized therapies, novel and repurposed medications, and a multidisciplinary approach is transforming bronchiectasis from a condition that once had few treatment options into one that offers hope for improved management and even disease stabilization.
-
OSA and the Alzheimer’s continuum
OSA is being increasingly recognized as a potential contributor to neurodegeneration, particularly in the preclinical stages of Alzheimer’s disease. As early intervention becomes a priority in Alzheimer’s prevention, sleep disorders are being investigated as modifiable risk factors.
-
CHEST to offer first-of-its-kind certification for APPs in critical care
For APPs in the critical care setting, this certification exam will be a valuable way to validate their knowledge and competence in the ICU.
-
Aspergillus in bronchiectasis: An expanding spectrum of disease and diagnostic challenge
Recent findings underscore the need to integrate Aspergillus serologies into routine bronchiectasis care and adopt a phenotype-driven, personalized approach to fungal surveillance and treatment.
-
In our navigational bronchoscopy ERA
The VERITAS trial is a turning point for interventional pulmonology, ushering in an era of high-quality comparative effectiveness trials poised to transform our approach to technology evaluation, implementation, and, ultimately, patient care.
-
Airway pressure release ventilation: Should it be used in the early stages of ARDS?
APRV has traditionally been viewed as a salvage therapy for patients with ARDS, but recent literature suggests that it can provide better overall lung recruitment with less sedation and more ventilator-free days.